Source comparison
MOTS-c Nasal Absorption: Delivery Method Comparison
Intranasal 10–20 minutes 30–70% None. Bypasses hepatic metabolism Requires proper formulation pH (5.5–6.5); mucosal irritation possible with poor formulations; precise dosing per spray Optimal for research requiring rapid onset and proteolytic protection; form
This comparison does not assign a generated winner or score.
- Intranasal
- 10–20 minutes
- 30–70%
- None. Bypasses hepatic metabolism
- Requires proper formulation pH (5.5–6.5); mucosal irritation possible with poor formulations; precise dosing per spray
- Optimal for research requiring rapid onset and proteolytic protection; formulation quality is the determining factor
- Subcutaneous Injection
- 45–90 minutes
- 80–95%
- Minimal
- Requires reconstitution; injection site reactions; technique-dependent; cold chain storage
- Gold standard for consistent bioavailability but slower onset; preferred when peak concentration timing is less critical
- Oral (Capsule/Tablet)
- N/A
- <5% (estimated)
- Complete degradation in GI tract and liver
- Convenient but pharmacologically ineffective for peptides; gastric proteases cleave bonds before absorption
- Not viable for MOTS-c. Peptide structure cannot survive gastrointestinal transit intact
- Sublingual
- 15–30 minutes
- 15–40% (estimated)
- Partial bypass via oral mucosa
- Variable absorption; swallowing reduces efficacy; less mucosal surface area than nasal cavity
- Theoretical alternative but less studied than intranasal; no validated MOTS-c formulations currently available
- This comparison underscores why mots-c nasal absorption has gained research interest: it combines the convenience of non-invasive delivery with bioavailability approaching injectable routes, while eliminating the enzymatic degradation that makes oral peptide delivery impractical.